This is a pre-revenue, early-stage veterinary drug development collaboration with no disclosed financial terms or regulatory milestones. Monitor for INAD submission and any subsequent capital raises to fund the program, as Splash's $2M market cap suggests financing risk. No immediate trading catalyst — the stock may see speculative volume but fundamentals are unchanged.
Price Chart
Executive Summary
Splash Beverage Group announced a collaboration with Lupvindol Biosciences to advance CannEpil through the FDA veterinary pathway for companion-animal oncology and chronic pain. Splash retains ownership of all resulting data, IP, and commercialization rights. The program is milestone-driven with no disclosed financial terms, and CannEpil has not received any FDA approval — the filing is a non-financial strategic update with no revenue or earnings impact.
Key Facts
- Splash entered a collaboration agreement with Lupvindol Biosciences to develop CannEpil for FDA veterinary approval.
- Initial focus is on canine oncology and chronic pain management.
- Splash retains ownership of all medical technology, study data, regulatory submissions, and foreground IP.
- The program is milestone-driven with an initial payment and subsequent milestone payments; no dollar amounts disclosed.
- CannEpil has not been approved by the FDA for veterinary use — no assurance of regulatory authorization.
- The global veterinary pain-management market was valued at approximately $2.6 billion in 2024, projected to reach $3.8 billion by 2030.
- The collaboration is led by Hunter Land, Ph.D., former GW Pharma R&D executive who worked on Epidiolex and Sativex.
Financial Impact
No financial figures disclosed. Milestone-based funding with a contractual funding cap for FDA-required pilot studies. Lupvindol absorbs annual FDA sponsor fee through Conditional Approval.
Risk Factors
- No assurance CannEpil will receive any FDA regulatory authorization (conditional or full approval).
- Splash must raise additional capital to fund the program — risk of dilutive financing given $2M market cap.
- The company's ability to maintain the CannEpil license from Argent Biopharma is a contractual dependency.
- Competitors may market the same or similar products.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001731122-26-001020 |
| Document: e7828_ex99-1.htm | 0001731122-26-001020 |
| Document: 0001731122-26-001020-index-headers.html | 0001731122-26-001020 |
| Document: 0001731122-26-001020-index.html | 0001731122-26-001020 |
| Document: 0001731122-26-001020.txt | 0001731122-26-001020 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | DEFA14A | — | awaiting T+5 | — | — |
Aug 25, 2026 8w ago | 8-K | $0.4715 | awaiting T+5 | — | — |
Aug 21, 2026 9w ago | 8-K | $0.4376 | awaiting T+5 | — | — |
Aug 20, 2026 9w ago | 8-K | $0.4250 | awaiting T+5 | — | — |
Aug 12, 2026 10w ago | 8-K | $0.4096 $0.4104 | ▲ +0.20% | ▲ +0.64% | — |
Aug 7, 2026 11w ago | S-1 | $0.4122 $0.3780 | ▲ +8.30% | ▲ +8.25% | — |
Aug 5, 2026 11w ago | 8-K | $0.4250 $0.4096 | ▼ −3.62% | ▼ −3.97% | — |
Jul 14, 2026 14w ago | 8-K | $0.1043 $0.0936 | ▼ −10.26% | ▼ −9.79% | — |
Jul 9, 2026 15w ago | 8-K | $0.1653 $0.0936 | ▲ +43.38% | ▲ +43.24% | — |
Jul 6, 2026 16w ago | 8-K | $0.2081 $0.1240 | ▼ −40.41% | ▼ −40.13% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers